SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-049281
Filing Date
2024-11-26
Accepted
2024-11-26 16:19:50
Documents
15
Period of Report
2024-11-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K arwr-20241126.htm   iXBRL 8-K 29372
2 EX-99.1 arwr-202411268kex991.htm EX-99.1 77161
6 ghvnqo5ppwcq000001.jpg GRAPHIC 49974
  Complete submission text file 0001628280-24-049281.txt   315289

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT arwr-20241126.xsd EX-101.SCH 1812
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT arwr-20241126_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT arwr-20241126_pre.xml EX-101.PRE 13066
17 EXTRACTED XBRL INSTANCE DOCUMENT arwr-20241126_htm.xml XML 2829
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Filer) CIK: 0000879407 (see all company filings)

IRS No.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38042 | Film No.: 241504129
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)